{"protocolSection": {"identificationModule": {"nctId": "NCT00097500", "orgStudyIdInfo": {"id": "2993-114"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes", "officialTitle": "A Phase 3, Randomized, Open Label, Comparator-Controlled, Parallel Group, Multicenter Study to Compare the Effects of Exenatide and Insulin Glargine on Beta Cell Function and Cardiovascular Risk Markers in Subjects With Type 2 Diabetes Treated With Metformin Who Have Not Achieved Target HbA1c"}, "statusModule": {"statusVerifiedDate": "2015-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2004-09"}, "primaryCompletionDateStruct": {"date": "2009-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2004-11-24", "studyFirstSubmitQcDate": "2004-11-24", "studyFirstPostDateStruct": {"date": "2004-11-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-12-24", "resultsFirstSubmitQcDate": "2010-12-24", "resultsFirstPostDateStruct": {"date": "2011-01-10", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-03-19", "lastUpdatePostDateStruct": {"date": "2015-04-07", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}, "collaborators": [{"name": "Eli Lilly and Company", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (Lantus\u00ae injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["diabetes", "exenatide", "exendin-4", "Amylin", "Lilly"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 69, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Exenatide Arm", "type": "EXPERIMENTAL", "description": "Exenatide and Metformin", "interventionNames": ["Drug: exenatide", "Drug: Metformin"]}, {"label": "Insulin Glargine Arm", "type": "ACTIVE_COMPARATOR", "description": "Insulin Glargine and Metformin", "interventionNames": ["Drug: Insulin glargine", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "exenatide", "description": "subcutaneous injection, titrated up to a maximum of 20mcg three times a day in order to meet defined blood glucose targets", "armGroupLabels": ["Exenatide Arm"], "otherNames": ["Byetta"]}, {"type": "DRUG", "name": "Insulin glargine", "description": "subcutaneous injection, once a day, titrated as necessary in order to meet defined blood glucose targets", "armGroupLabels": ["Insulin Glargine Arm"], "otherNames": ["Lantus"]}, {"type": "DRUG", "name": "Metformin", "description": "Patients usual dosage", "armGroupLabels": ["Exenatide Arm", "Insulin Glargine Arm"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Beta-cell Function After 52 Weeks of Therapy", "description": "Treatment effect on beta-cell function as measured by the ratio of Week 52 arginine-stimulated insulin secretion during a hyperglycemic clamp(specifically, the incremental AUC of insulin with respect to basal value over a 10 min period \\[i.e., clamp time 290 min to 300 min\\]) to that at baseline (i.e., the ratio is calculated as arginine-stimulated insulin secretion at week 52 divided by arginine-stimulated insulin secretion at baseline \\[week -2\\]).", "timeFrame": "Baseline (week -2) and 52 weeks"}], "secondaryOutcomes": [{"measure": "Beta-cell Function 4 Weeks After Cessation of Therapy", "description": "Treatment effect on beta-cell function as measured by the ratio of Week 56 arginine-stimulated insulin secretion during a hyperglycemic clamp(specifically, the incremental AUC of insulin with respect to basal value over a 10 min period \\[i.e., clamp time 290 min to 300 min\\]) to that at baseline (i.e., the ratio is calculated as arginine-stimulated insulin secretion at week 56 divided by arginine-stimulated insulin secretion at baseline \\[week -2\\]).", "timeFrame": "Baseline (week -2) and 56 weeks"}, {"measure": "Change in First Phase C-peptide Release", "description": "Ratio of first phase C-peptide response to glucose at 52 weeks (end of on-drug period) and 56 weeks (during off-drug period) compared to first phase C-peptide response to glucose at baseline (i.e., C-peptide response to glucose at week 52 or week 56 divided by C-peptide response to glucose at baseline \\[week -2\\]). C-peptide is measured as a surrogate marker of insulin secretion. First phase C-peptide/insulin release is measured during the first ten minutes of glucose infusion during a hyperglycemic clamp procedure.", "timeFrame": "baseline (week -2), 52 weeks, and 56 weeks"}, {"measure": "Change in Second Phase C-peptide Release", "description": "Ratio of second phase C-peptide response to glucose at 52 weeks (end of on-drug period) and 56 weeks (during off-drug period) compared to second phase C-peptide response to glucose at baseline (i.e., C-peptide response to glucose at week 52 or week 56 divided by C-peptide response to glucose at baseline \\[week -2\\]). C-peptide is measured as a surrogate marker of insulin secretion. Second phase C-peptide/insulin release is measured from time=10 minutes to time=80 minutes of glucose infusion during a hyperglycemic clamp procedure.", "timeFrame": "baseline (-2 weeks), 52 weeks, and 56 weeks"}, {"measure": "Change in Glycosylated Hemoglobin (HbA1c)", "description": "Change in HbA1c from week 0 to week 52 (i.e., HbA1c at week 52 minus HbA1c at week 0).", "timeFrame": "Week 0 and week 52"}, {"measure": "Change in Fasting Plasma Glucose", "description": "Change in fasting plasma glucose from week 0 to week 52 (i.e., fasting plasma glucose at week 52 minus fasting plasma glucose at week 0).", "timeFrame": "0 weeks and 52 weeks"}, {"measure": "Seven Point Self Monitored Blood Glucose (SMBG) Measurements", "description": "SMBG measured at 7 time points (before and after breakfast, before and after lunch, before and after dinner, at bedtime).", "timeFrame": "0 weeks and 52 weeks"}, {"measure": "Change in Body Weight", "description": "Change in body weight from week 0 to week 52 (i.e., body weight at week 52 minus body weight at week 0).", "timeFrame": "0 weeks and 52 weeks"}, {"measure": "M-value at Baseline, Week 52 and Week 56", "description": "M-value at baseline (week -2), week 52 (end of on-drug period), and week 56 (during off-drug period). Insulin sensitivity was assessed during the euglycemic/hyperglycemic clamp test at baseline (week -2), week 52, and week 56. Insulin-mediated glucose uptake (M-value) was calculated as the mean glucose requirement during the 90-120 minute interval of the clamp.", "timeFrame": "baseline (week -2), 52 weeks, and 56 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of type 2 diabetes, but otherwise healthy\n* HbA1c between 6.6% and 9.5%, inclusive.\n* Body mass index (BMI) of 25 kg/m2 to 40 kg/m2, inclusive.\n* Treated with a stable dose of metformin for at least 2 months prior to screening.\n\nExclusion Criteria:\n\n* Patients previously in a study using exenatide.\n* Treated with oral anti-diabetic medications other than metformin within 2 months of screening (thiazolidinediones within 5 months of screening).\n* Treated with insulin within 3 months of screening.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "30 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Vice President, Research and Development, MD", "affiliation": "Amylin Pharmaceuticals, LLC.", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Helsinki", "country": "Finland", "geoPoint": {"lat": 60.16952, "lon": 24.93545}}, {"facility": "Research Site", "city": "Amsterdam", "country": "Netherlands", "geoPoint": {"lat": 52.37403, "lon": 4.88969}}, {"facility": "Research Site", "city": "Goteborg", "country": "Sweden", "geoPoint": {"lat": 57.70716, "lon": 11.96679}}]}, "referencesModule": {"references": [{"pmid": "19196887", "type": "RESULT", "citation": "Bunck MC, Diamant M, Corner A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Jarvinen H, Heine RJ. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009 May;32(5):762-8. doi: 10.2337/dc08-1797. Epub 2009 Feb 5."}, {"pmid": "31078666", "type": "DERIVED", "citation": "Muskiet MHA, Bunck MC, Heine RJ, Corner A, Yki-Jarvinen H, Eliasson B, Joles JA, Diamant M, Tonneijck L, van Raalte DH. Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial. Diabetes Res Clin Pract. 2019 Jul;153:14-22. doi: 10.1016/j.diabres.2019.05.001. Epub 2019 May 9."}, {"pmid": "21868779", "type": "DERIVED", "citation": "Bunck MC, Corner A, Eliasson B, Heine RJ, Shaginian RM, Taskinen MR, Smith U, Yki-Jarvinen H, Diamant M. Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care. 2011 Sep;34(9):2041-7. doi: 10.2337/dc11-0291."}, {"pmid": "20494360", "type": "DERIVED", "citation": "Bunck MC, Corner A, Eliasson B, Heine RJ, Shaginian RM, Wu Y, Yan P, Smith U, Yki-Jarvinen H, Diamant M, Taskinen MR. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis. 2010 Sep;212(1):223-9. doi: 10.1016/j.atherosclerosis.2010.04.024. Epub 2010 Apr 29."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Exenatide Arm", "description": "5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks. After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability."}, {"id": "FG001", "title": "Insulin Glargine Arm", "description": "Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements."}], "periods": [{"title": "On-drug Period (Week 0 to Week 52)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "numSubjects": "33"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Subjects experiencing loss of glucose control after Week 52 are considered to have completed study.", "numSubjects": "30"}, {"groupId": "FG001", "comment": "Subjects experiencing loss of glucose control after Week 52 are considered to have completed study.", "numSubjects": "30"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Withdrawal of consent", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}, {"title": "Off-drug Period (Week 52 to Week 64)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Exenatide is discontinued, metformin is continued", "numSubjects": "30"}, {"groupId": "FG001", "comment": "Insulin Glargine is discontinued, metformin is continued", "numSubjects": "30"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "26"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Withdrawal of consent", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Loss of glucose control", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Exenatide Arm", "description": "5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks. After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability."}, {"id": "BG001", "title": "Insulin Glargine Arm", "description": "Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "33"}, {"groupId": "BG002", "value": "69"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58.4", "spread": "8.4"}, {"groupId": "BG001", "value": "58.3", "spread": "7.3"}, {"groupId": "BG002", "value": "58.4", "spread": "7.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "24"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "45"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "30.87", "spread": "4.15"}, {"groupId": "BG001", "value": "30.13", "spread": "3.49"}, {"groupId": "BG002", "value": "30.52", "spread": "3.84"}]}]}]}, {"title": "Body weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "90.56", "spread": "12.66"}, {"groupId": "BG001", "value": "92.39", "spread": "13.56"}, {"groupId": "BG002", "value": "91.44", "spread": "13.03"}]}]}]}, {"title": "Glycosylated hemoglobin (HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.58", "spread": "0.89"}, {"groupId": "BG001", "value": "7.41", "spread": "0.81"}, {"groupId": "BG002", "value": "7.50", "spread": "0.85"}]}]}]}, {"title": "Duration of diabetes", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.72", "spread": "4.70"}, {"groupId": "BG001", "value": "3.97", "spread": "3.62"}, {"groupId": "BG002", "value": "4.88", "spread": "4.28"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Beta-cell Function After 52 Weeks of Therapy", "description": "Treatment effect on beta-cell function as measured by the ratio of Week 52 arginine-stimulated insulin secretion during a hyperglycemic clamp(specifically, the incremental AUC of insulin with respect to basal value over a 10 min period \\[i.e., clamp time 290 min to 300 min\\]) to that at baseline (i.e., the ratio is calculated as arginine-stimulated insulin secretion at week 52 divided by arginine-stimulated insulin secretion at baseline \\[week -2\\]).", "populationDescription": "Evaluable population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ratio", "timeFrame": "Baseline (week -2) and 52 weeks", "groups": [{"id": "OG000", "title": "Exenatide Arm", "description": "5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks. After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability."}, {"id": "OG001", "title": "Insulin Glargine Arm", "description": "Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.89", "spread": "0.27"}, {"groupId": "OG001", "value": "1.15", "spread": "0.11"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Beta-cell Function 4 Weeks After Cessation of Therapy", "description": "Treatment effect on beta-cell function as measured by the ratio of Week 56 arginine-stimulated insulin secretion during a hyperglycemic clamp(specifically, the incremental AUC of insulin with respect to basal value over a 10 min period \\[i.e., clamp time 290 min to 300 min\\]) to that at baseline (i.e., the ratio is calculated as arginine-stimulated insulin secretion at week 56 divided by arginine-stimulated insulin secretion at baseline \\[week -2\\]).", "populationDescription": "Evaluable population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ratio", "timeFrame": "Baseline (week -2) and 56 weeks", "groups": [{"id": "OG000", "title": "Exenatide Arm", "description": "5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks. After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability."}, {"id": "OG001", "title": "Insulin Glargine Arm", "description": "Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.02", "spread": "0.06"}, {"groupId": "OG001", "value": "1.08", "spread": "0.07"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4185", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in First Phase C-peptide Release", "description": "Ratio of first phase C-peptide response to glucose at 52 weeks (end of on-drug period) and 56 weeks (during off-drug period) compared to first phase C-peptide response to glucose at baseline (i.e., C-peptide response to glucose at week 52 or week 56 divided by C-peptide response to glucose at baseline \\[week -2\\]). C-peptide is measured as a surrogate marker of insulin secretion. First phase C-peptide/insulin release is measured during the first ten minutes of glucose infusion during a hyperglycemic clamp procedure.", "populationDescription": "Evaluable population. Last observation carried forward.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ratio", "timeFrame": "baseline (week -2), 52 weeks, and 56 weeks", "groups": [{"id": "OG000", "title": "Exenatide Arm", "description": "5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks. After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability."}, {"id": "OG001", "title": "Insulin Glargine Arm", "description": "Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "30"}]}], "classes": [{"title": "52 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.72", "spread": "0.11"}, {"groupId": "OG001", "value": "1.13", "spread": "0.07"}]}]}, {"title": "56 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.95", "spread": "0.05"}, {"groupId": "OG001", "value": "1.06", "spread": "0.06"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Statistical analysis at week 52.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Statistical analysis at week 56.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1188", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in Second Phase C-peptide Release", "description": "Ratio of second phase C-peptide response to glucose at 52 weeks (end of on-drug period) and 56 weeks (during off-drug period) compared to second phase C-peptide response to glucose at baseline (i.e., C-peptide response to glucose at week 52 or week 56 divided by C-peptide response to glucose at baseline \\[week -2\\]). C-peptide is measured as a surrogate marker of insulin secretion. Second phase C-peptide/insulin release is measured from time=10 minutes to time=80 minutes of glucose infusion during a hyperglycemic clamp procedure.", "populationDescription": "Evaluable population. Last observation carried forward.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ratio", "timeFrame": "baseline (-2 weeks), 52 weeks, and 56 weeks", "groups": [{"id": "OG000", "title": "Exenatide Arm", "description": "5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks. After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability."}, {"id": "OG001", "title": "Insulin Glargine Arm", "description": "Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}]}], "classes": [{"title": "52 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.88", "spread": "0.18"}, {"groupId": "OG001", "value": "1.01", "spread": "0.07"}]}]}, {"title": "56 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.00", "spread": "0.05"}, {"groupId": "OG001", "value": "1.08", "spread": "0.06"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Statistical analysis at week 52.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Statistical analysis at week 56.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1996", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in Glycosylated Hemoglobin (HbA1c)", "description": "Change in HbA1c from week 0 to week 52 (i.e., HbA1c at week 52 minus HbA1c at week 0).", "populationDescription": "Intent to treat population. Last observation carried forward.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent", "timeFrame": "Week 0 and week 52", "groups": [{"id": "OG000", "title": "Exenatide Arm", "description": "5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks. After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability."}, {"id": "OG001", "title": "Insulin Glargine Arm", "description": "Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "33"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.97", "spread": "0.14"}, {"groupId": "OG001", "value": "-0.87", "spread": "0.15"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5522", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in Fasting Plasma Glucose", "description": "Change in fasting plasma glucose from week 0 to week 52 (i.e., fasting plasma glucose at week 52 minus fasting plasma glucose at week 0).", "populationDescription": "Intent to treat population. Last observation carried forward.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "0 weeks and 52 weeks", "groups": [{"id": "OG000", "title": "Exenatide Arm", "description": "5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks. After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability."}, {"id": "OG001", "title": "Insulin Glargine Arm", "description": "Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "33"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.53", "spread": "0.25"}, {"groupId": "OG001", "value": "-3.10", "spread": "0.27"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Seven Point Self Monitored Blood Glucose (SMBG) Measurements", "description": "SMBG measured at 7 time points (before and after breakfast, before and after lunch, before and after dinner, at bedtime).", "populationDescription": "Intent to treat population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "0 weeks and 52 weeks", "groups": [{"id": "OG000", "title": "Exenatide Arm", "description": "5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks. After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability."}, {"id": "OG001", "title": "Insulin Glargine Arm", "description": "Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "33"}]}], "classes": [{"title": "Pre-breakfast measurement (week 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.92", "spread": "1.80"}, {"groupId": "OG001", "value": "8.38", "spread": "1.91"}]}]}, {"title": "Pre-breakfast measurement (week 52)", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.27", "spread": "1.63"}, {"groupId": "OG001", "value": "5.63", "spread": "0.85"}]}]}, {"title": "2-hour post-breakfast measurement (week 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.00", "spread": "2.58"}, {"groupId": "OG001", "value": "11.17", "spread": "3.30"}]}]}, {"title": "2-hour post-breakfast measurement (week 52)", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.98", "spread": "2.42"}, {"groupId": "OG001", "value": "7.53", "spread": "2.16"}]}]}, {"title": "Pre-lunch measurement (week 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.14", "spread": "2.25"}, {"groupId": "OG001", "value": "8.54", "spread": "2.51"}]}]}, {"title": "Pre-lunch measurement (week 52)", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.52", "spread": "1.52"}, {"groupId": "OG001", "value": "6.24", "spread": "1.66"}]}]}, {"title": "2-hour post-lunch measurement (week 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.90", "spread": "2.54"}, {"groupId": "OG001", "value": "10.52", "spread": "2.96"}]}]}, {"title": "2-hour post-lunch measurement (week 52)", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.97", "spread": "2.01"}, {"groupId": "OG001", "value": "8.15", "spread": "1.77"}]}]}, {"title": "Pre-dinner measurement (week 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.38", "spread": "2.40"}, {"groupId": "OG001", "value": "8.07", "spread": "2.48"}]}]}, {"title": "Pre-dinner measurement (week 52)", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.53", "spread": "2.63"}, {"groupId": "OG001", "value": "6.98", "spread": "2.04"}]}]}, {"title": "2-hour post-dinner measurement (week 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.42", "spread": "2.42"}, {"groupId": "OG001", "value": "10.26", "spread": "2.82"}]}]}, {"title": "2-hour post-dinner measurement (week 52)", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.98", "spread": "2.25"}, {"groupId": "OG001", "value": "8.81", "spread": "2.03"}]}]}, {"title": "Bedtime measurement (week 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.76", "spread": "2.44"}, {"groupId": "OG001", "value": "9.85", "spread": "3.09"}]}]}, {"title": "Bedtime measurement (week 52)", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.61", "spread": "2.11"}, {"groupId": "OG001", "value": "8.03", "spread": "2.82"}]}]}]}, {"type": "SECONDARY", "title": "Change in Body Weight", "description": "Change in body weight from week 0 to week 52 (i.e., body weight at week 52 minus body weight at week 0).", "populationDescription": "Intent to treat population. Last observation carried forward.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kg", "timeFrame": "0 weeks and 52 weeks", "groups": [{"id": "OG000", "title": "Exenatide Arm", "description": "5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks. After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability."}, {"id": "OG001", "title": "Insulin Glargine Arm", "description": "Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "33"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.80", "spread": "0.87"}, {"groupId": "OG001", "value": "0.75", "spread": "0.95"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "M-value at Baseline, Week 52 and Week 56", "description": "M-value at baseline (week -2), week 52 (end of on-drug period), and week 56 (during off-drug period). Insulin sensitivity was assessed during the euglycemic/hyperglycemic clamp test at baseline (week -2), week 52, and week 56. Insulin-mediated glucose uptake (M-value) was calculated as the mean glucose requirement during the 90-120 minute interval of the clamp.", "populationDescription": "Evaluable population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/min/kg", "timeFrame": "baseline (week -2), 52 weeks, and 56 weeks", "groups": [{"id": "OG000", "title": "Exenatide Arm", "description": "5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks. After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability."}, {"id": "OG001", "title": "Insulin Glargine Arm", "description": "Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}]}], "classes": [{"title": "baseline (week -2)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.24", "spread": "0.39"}, {"groupId": "OG001", "value": "2.79", "spread": "0.26"}]}]}, {"title": "week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.18", "spread": "0.42"}, {"groupId": "OG001", "value": "3.85", "spread": "0.32"}]}]}, {"title": "week 56", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.19", "spread": "0.44"}, {"groupId": "OG001", "value": "2.81", "spread": "0.29"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Total reporting period for adverse events is 64 weeks: a 52-week on-drug period followed by a 12-week off-drug period.", "eventGroups": [{"id": "EG000", "title": "Exenatide Arm", "description": "5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks. After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability.", "seriousNumAffected": 3, "seriousNumAtRisk": 36, "otherNumAffected": 32, "otherNumAtRisk": 36}, {"id": "EG001", "title": "Insulin Glargine Arm", "description": "Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements.", "seriousNumAffected": 1, "seriousNumAtRisk": 33, "otherNumAffected": 31, "otherNumAtRisk": 33}], "seriousEvents": [{"term": "Coronary Artery Stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Thrombophlebitis Superficial", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 33}]}], "otherEvents": [{"term": "Anemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 33}]}, {"term": "Abdominal Distension", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 33}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 33}]}, {"term": "Flatulence", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Injection Site Rash", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Edema Peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 33}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 33}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 33}]}, {"term": "Laryngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 33}]}, {"term": "Tooth Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 33}]}, {"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 33}]}, {"term": "Decreased Appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Hyperlipidemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 33}]}, {"term": "Hypoglycemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 33}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 33}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 33}]}, {"term": "Proteinuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 6.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 33}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Peter Ohman, Medical Science Director", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000069036", "term": "Insulin Glargine"}, {"id": "D000077270", "term": "Exenatide"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000097789", "term": "Glucagon-Like Peptide-1 Receptor Agonists"}, {"id": "D000019440", "term": "Anti-Obesity Agents"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M347", "name": "Insulin Glargine", "asFound": "Interaction", "relevance": "HIGH"}, {"id": "M1726", "name": "Exenatide", "asFound": "Bipolar", "relevance": "HIGH"}, {"id": "M29005", "name": "Islet Amyloid Polypeptide", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M3401", "name": "Glucagon-Like Peptide-1 Receptor Agonists", "relevance": "LOW"}, {"id": "M9043", "name": "Glucagon", "relevance": "LOW"}, {"id": "M26997", "name": "Glucagon-Like Peptide 1", "relevance": "LOW"}, {"id": "M21396", "name": "Anti-Obesity Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnObAg", "name": "Anti-Obesity Agents"}, {"abbrev": "Gast", "name": "Gastrointestinal Agents"}]}}, "hasResults": true}